All In Biotech

Drug Trial Radar · NCT06934538

First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer

Open Label, Multicenter, Dose-escalation and Cohort-expansion Phase I/IIA Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer (CRC) - BreAK CRC Trial (BreAK for Brenus Anti-cancer)

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Jun 17, 2025

Primary completion

Jun 2028

Study completion Jun 2029

Sponsor

Lead sponsor
Brenus PharmaIndustry
Sponsor type
Industry
First posted
Apr 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I/IIA, first-in-human (FIH), two-part, open-label, multicenter study to characterize the safety, tolerability profile, and clinical efficacy of STC-1010 associated with GM-CSF and cyclophosphamide immunostimulant (IS) regimen administered with standard of care (SOC) therapy (mFOLFOX6 with or without bevacizumab) to participants with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) colorectal cancer (CRC). The trial will be conducted in two parts: * A Phase I consisting of a dose escalation part and small expansion part to determine the maximum tolerated dose (MTD), recommended Phase II dose (RP2D) and safety profile of the STC-1010 + IS regimen administered with SOC therapy. Approximately 21 to 33 participants will be included in this phase in Europe. * A Phase IIA consisting of the expansion stage of the study which will further evaluate the clinical efficacy and safety of STC-1010 on a larger number of participants treated at the identified RP2D. Approximately 57 to 60 participants will be enrolled in total in 2 different arms. Multi-site recruitment will take place in Europe and in the US.

Conditions

  • Unresectable Metastatic Colorectal Cancer
  • Unresectable Locally Advanced Colorectal Cancer

Interventions

  • STC-1010 + IS regimen + SOC therapyBiological

    STC-1010 administered with immunostimulants (IS) in low-dose (cyclophosphamide and GM-CSF) and standard of care (SOC) therapy (mFOLFOX6 with or without bevacizumab)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: To determine overall safety profile, recommended Phase 2 dose (RP2D) and maximum tolerated dose (MTD)Time frame: 28 days
  2. Phase 2A: To determine the clinical efficacy by Progression Free Survival (PFS) rateTime frame: 12 months

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • Johns Hopkins

    Baltimore, Maryland · Not yet recruiting

  • Institut Jules Bordet

    Brussels, Belgium · Recruiting

  • Institut Bergonié

    Bordeaux, France · Recruiting

  • Centre Georges François Leclerc (CGFL)

    Dijon, France · Recruiting

  • Centre Léon Bérard (CLB)

    Lyon, France · Recruiting

  • Hospices Civils de Lyon (HCL)

    Lyon, France · Recruiting

  • Institut du Cancer de Montpellier (ICM)

    Montpellier, France · Recruiting

  • Centre Hospitalier Universitaire de Poitiers (CHU)

    Poitiers, France · Not yet recruiting

  • Institut Gustave Roussy (IGR)

    Villejuif, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.